Cadrenal Therapeutics(CVKD) - 2023 Q2 - Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | Name of each exchange on which | | --- | --- | --- | | Title of each class | Trading symbol(s) | registered | | Common Stock, par value $0.001 per share | CVKD | The Nasdaq Stock Market, LLC | | ...